Combination Therapies for Enhancing Protein Degradation
AssigneesThe Regents of the University of Michigan, President and Fellows of Harvard College
InventorsDaniel J. Finley, Jessica Robert, Monica Boselli, Jason E. Gestwicki, Xiaokai Li
Life of this patent
Estimating the term…
Abstract
Disclosed herein are combination therapies for enhancing protein degradation. One component is an inhibitor of USP14, while the second component is an inhibitor of Hsp70. In certain embodiments, the invention relates to methods of treating or preventing a tauopathy, such as Alzheimer's disease.
Claims17
A method of treating or preventing a tauopathy or a trinucleotide repeat disorder in a subject comprising co-administering to the subject
- an effective amount of a first compound, or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof, and
- an effective amount of a second compound, or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof,
- wherein the first compound inhibits Usp14 and the second compound inhibits Hsp70.
A method of enhancing degradation of a protein in a cell, comprising contacting the cell with
- an effective amount of a first compound, or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof, and
- an effective amount of a second compound, or a pharmaceutically acceptable salt, solvate, hydrate, prodrug, chemically-protected form, enantiomer or stereoisomer thereof,
- wherein the first compound inhibits Usp14 and the second compound inhibits Hsp70.
Dependencies are inferred from the claim text.